No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Shandong Boan Biotechnology to Sell Equipment for Nearly 32 Million Yuan Under Finance Lease Deal
Bohuan Bio (06955.HK): Entered into a financing lease agreement with Industrial Bank Financial Leasing.
On January 24, Gelonghui reports that Boan Biological (06955.HK) announced that on January 24, 2025, the company entered into a financing lease agreement with Industrial Gold Leasing, under which Industrial Gold Leasing will purchase leasing Assets from the company and lease the Assets back to the company during the lease term; however, it may terminate early according to the terms and conditions of the financing lease agreement. The Directors believe that entering into the financing lease agreement will strengthen the company's working capital situation and promote a more balanced and efficient long-term and short-term financing mix, thereby supporting the company's current and future market Business and Operation activities and achieving its Global Strategy goals.
HK stocks anomaly | BeiGene Bio (06955) rose nearly 9%, initial signs of company scale effect. The number of similar bio-similar drugs on the market continues to accumulate and trade volume is increasing.
Bohai Biological (06955) increased by nearly 9%. As of the time of writing, it rose by 8.92%, priced at 8.3 Hong Kong dollars, with a transaction volume of 15.9053 million Hong Kong dollars.
[Focus on Brokerage] Zhongtai initiates coverage of Boan Biotech (06955) with a "shareholding" rating, indicating that the progress of listing products in relevant fields is leading among similar products.
Jingu Cai Xun | Zhongtai Securities issued research reports indicating that Boan Biologics (06955) continues to accumulate and expand its listing of biosimilar varieties. The revenue in 2021/2022/2023 reached 0.16, 0.52, 0.62 billion yuan respectively, and the revenue in the first half of 2024 reached 0.36 billion yuan. The company's economies of scale are beginning to show, with sales expense ratio, management expense ratio, and research and development expense ratio (R&D spending in 2024H1 decreased by approximately 40.2 million yuan. This is mainly due to the increase in R&D investment capitalization in the second half of 2023, with more R&D projects progressing to Phase III clinical trials and capitalization).
Additional Considerations Required While Assessing Shandong Boan Biotechnology's (HKG:6955) Strong Earnings
Is Shandong Boan Biotechnology (HKG:6955) Using Too Much Debt?